Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study

MeSH terms

• Antibodies, Monoclonal, Humanized / therapeutic use
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Dexamethasone / adverse effects
• Humans
• Lenalidomide / adverse effects
• Multiple Myeloma* / diagnosis
• Multiple Myeloma* / drug therapy